Armata Pharmaceuticals, Inc. 8-K

Summary

FDA Fast Track designation for AP-SA02, Armata’s intravenous multi-phage candidate for adjunct treatment of complicated MSSA or MRSA bacteremia. The designation enables more frequent FDA interactions and rolling review of a Biologics License Application; Accelerated Approval and Priority Review may also be available if supported by clinical data.

Key Figures

• Phase 3 superiority study in complicated S. aureus bacteremia anticipated to begin in H2 2026.

Investor Takeaways

• Watch for initiation of the Phase 3 study in H2 2026 and subsequent clinical data that could support the candidate’s development and potential eligibility for expedited review.